Northwest Biotherapeutics, Inc (OTCMKTS:NWBO), which is a leading biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers has today made it public that it indeed closed on the $7.5 million financing deal yesterday.
The company sold quite a large number of its securities to numerous institutional securities. The various investors in the company were served with five year Class A warrants to buy up to about 21.6 million shares of common stock with an accompanying price of $0.26 for each share.
Additionally, they are also set to receive three month Class B warrants which will facilitate the purchase of about 21.6 million shares of common stock and that will be with an accompanying exercise price of $1.00 per share.
Over the years, this top company which has been performing at per with most of the Top Biotech Stocks has been developing various personalized immunotherapy products which have been treating cancers quite effectively. Just as it is normally the case with most of the Best Biotech Stocks, Northwest Biotherapeutics, Inc has been facing quite a wide range of challenges.
For instance, it went through difficult times last year after some accusations were leveled against it. The company had been blamed for setting up poor governance and needed to be delisted from the big boards as was revealed by some sources close to the company. The tumultuous moment was a major testing period for the company and later on some welcoming news showed up.
It was a moment of great relief when the company announced the partial clinical hold on the trial had been lifted by the responsible body, FDA.
A lot of things might be said about Northwest Biotherapeutics, Inc, but one thing is for sure –the biotechnology company develops personalized immunotherapy products which are quite effective in dealing with cancers and cannot be compared to the existing methods which are quite inferior. The company’s solutions are cost-effective and are free from the toxicities associated with chemotherapies.
This is the company to watch at the moment and its competitors can’t help but see the way it is utilizing its broad platform technology for DCVax dendritic cell-based vaccines!